-
Posted by
Two Blokes Jun 13 -
Filed in
Stock
-
7 views
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF), a biotechnology firm specialising in allergy treatments, is showcasing key research findings at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Glasgow. Highlights include promising initial results from its peanut allergy vaccine candidate, which demonstrated safety and a significant reduction in allergic reactions in early human trials.
